Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654623 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A Phase 3 study of Advanced Breast Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
- 20
- Study locations
NCT05654623 is a Phase 3 study of Advanced Breast Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 624 participants, above the 442-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT05654623, a Phase 3 study of Advanced Breast Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG ARV-471
Study Locations (20)
Florida
- Florida Cancer Specialists - Altamonte Springs
- Florida Cancer Specialists BON - Bonita Springs
- Florida Cancer Specialists BCC - Bradenton
- Florida Cancer Specialists LRS - Bradenton
- Florida Cancer Specialists - Brandon
- Florida Cancer Specialists NFM - Cape Coral
- Morton Plant Hospital - BayCare Health System - Clearwater
- Florida Cancer Specialists - Clearwater
- Florida Cancer Specialists - Daytona Beach
California
- California Cancer Associates for Research and Excellence, Inc. (cCARE) - Encinitas
- Orange Coast Memorial Medical Center - Fountain Valley
- California Cancer Associates for Research and Excellence - Fresno
- Providence Queen of the Valley Medical Center - Napa
- California Cancer Associates for Research and Excellence - San Marcos
- Olive View-UCLA Medical Center - Sylmar
Connecticut
- Smilow Cancer Hospital Care Center at Fairfield - Fairfield
- Smilow Cancer Hospital at Yale-New Haven - New Haven
- Yale-New Haven Hospital - New Haven
- Smilow Cancer Hospital Care Center at North Haven - North Haven
- Smilow Cancer Hospital Care Center at Trumbull - Trumbull
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654623
The ClinicalTrials.gov registry entry for NCT05654623 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 442-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (41% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT05654623 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05654623 about?
NCT05654623 is a clinical study titled "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer". A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
What is the current status of trial NCT05654623?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2023-03-03. Estimated completion is 2028-05-15.
What conditions does trial NCT05654623 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT05654623?
The interventions under investigation include: Fulvestrant (DRUG), ARV-471 (DRUG).
Who is sponsoring clinical trial NCT05654623?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05654623 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RECRUITING · Phase 3
-
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
RECRUITING · Phase 3
-
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
-
Engage Psychosocial Intervention for Cancer Symptoms
RECRUITING · NA
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.